Zosano Pharma Stock Forecast, Price & News

+0.02 (+2.82 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.15 million shs
Average Volume5.16 million shs
Market Capitalization$84.38 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZSAN News and Ratings via Email

Sign-up to receive the latest news and ratings for Zosano Pharma and its competitors with MarketBeat's FREE daily newsletter.

Zosano Pharma logo

About Zosano Pharma

Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system. The company was founded in October 2006 and is headquartered in Fremont, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.81 out of 5 stars

Medical Sector

771st out of 1,351 stocks

Pharmaceutical Preparations Industry

374th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zosano Pharma (NASDAQ:ZSAN) Frequently Asked Questions

Is Zosano Pharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Zosano Pharma stock.
View analyst ratings for Zosano Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Zosano Pharma?

Wall Street analysts have given Zosano Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zosano Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zosano Pharma?

Zosano Pharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 4,910,000 shares, a decrease of 25.4% from the August 15th total of 6,580,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is currently 3.8 days. Approximately 7.2% of the company's shares are short sold.
View Zosano Pharma's Short Interest

When is Zosano Pharma's next earnings date?

Zosano Pharma is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Zosano Pharma

How were Zosano Pharma's earnings last quarter?

Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02.
View Zosano Pharma's earnings history

How has Zosano Pharma's stock been impacted by Coronavirus?

Zosano Pharma's stock was trading at $0.5662 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZSAN stock has increased by 28.9% and is now trading at $0.73.
View which stocks have been most impacted by COVID-19

When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?

Shares of Zosano Pharma reverse split on Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2018. An investor that had 100 shares of Zosano Pharma stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ZSAN?

3 Wall Street analysts have issued 1 year price objectives for Zosano Pharma's stock. Their forecasts range from $2.00 to $2.50. On average, they anticipate Zosano Pharma's share price to reach $2.17 in the next twelve months. This suggests a possible upside of 196.8% from the stock's current price.
View analysts' price targets for Zosano Pharma
or view top-rated stocks among Wall Street analysts.

Who are Zosano Pharma's key executives?

Zosano Pharma's management team includes the following people:
  • Steven Lo, President, Chief Executive Officer & Director
  • Hayley Lewis, Senior Vice President-Operations
  • Christine Matthews, Chief Financial Officer
  • Donald J. Kellerman, VP-Clinical Development & Medical Affairs

Who are some of Zosano Pharma's key competitors?

What other stocks do shareholders of Zosano Pharma own?

When did Zosano Pharma IPO?

(ZSAN) raised $47 million in an initial public offering on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.

What is Zosano Pharma's stock symbol?

Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."

Who are Zosano Pharma's major shareholders?

Zosano Pharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.96%), BlackRock Inc. (1.91%), Renaissance Technologies LLC (1.17%), Geode Capital Management LLC (0.83%), GSA Capital Partners LLP (0.82%) and State Street Corp (0.36%). Company insiders that own Zosano Pharma stock include Deirdre Mary Bigley, Hayley Lewis and Steven Lo.
View institutional ownership trends for Zosano Pharma

Which major investors are selling Zosano Pharma stock?

ZSAN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Citadel Advisors LLC. Company insiders that have sold Zosano Pharma company stock in the last year include Deirdre Mary Bigley, Hayley Lewis, and Steven Lo.
View insider buying and selling activity for Zosano Pharma
or view top insider-selling stocks.

Which major investors are buying Zosano Pharma stock?

ZSAN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, State Street Corp, Vanguard Group Inc., Virtu Financial LLC, Geode Capital Management LLC, Millennium Management LLC, and Telemetry Investments L.L.C..
View insider buying and selling activity for Zosano Pharma
or or view top insider-buying stocks.

How do I buy shares of Zosano Pharma?

Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zosano Pharma's stock price today?

One share of ZSAN stock can currently be purchased for approximately $0.73.

How much money does Zosano Pharma make?

Zosano Pharma has a market capitalization of $84.38 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-33,370,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How many employees does Zosano Pharma have?

Zosano Pharma employs 45 workers across the globe.

What is Zosano Pharma's official website?

The official website for Zosano Pharma is

Where are Zosano Pharma's headquarters?

Zosano Pharma is headquartered at 34790 ARDENTECH COURT, FREMONT CA, 94555.

How can I contact Zosano Pharma?

Zosano Pharma's mailing address is 34790 ARDENTECH COURT, FREMONT CA, 94555. The biotechnology company can be reached via phone at (510) 745-1200 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.